Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of 89Zr-CB307 in PSMA+ Tumours
NCT05836623Phase 1Active, not recruiting
- Sponsor
- Crescendo Biologics
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-CB307 in solid tumor and prostate cancer (PCa) (2 arms), sponsored by Crescendo Biologics. Primary endpoints: Incidence of adverse events up to 8 months, Maximum standardized uptake value up to 8 months and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
89Zr-CB307
03
Conditions
solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05836623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836623.